Clinical Trials Browser

Phase 2 × Recruiting × Unresectable Non-small Cell Lung Cancer × Clear all

NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Phase 2 Recruiting

Unresectable Non-small Cell Lung Cancer